Novo Nordisk recently published favorable results from the FLOW renal outcomes trial, which found that Ozempic (semaglutide) 1.0 mg lowered the risk of kidney disease progression and kidney and ...

The FDA's approval is based on the results of the FLOW phase 3b kidney outcomes trial. The trial revealed that Ozempic® 1 mg significantly lowered the relative risk of worsening kidney disease, kidney ...

Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist, or GLP-1 RA, known as semaglutide. The latest FDA approval makes the medication the first GLP-1 treatment option for people with type ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

The FDA approved Ozempic to treat kidney disease in Type 2 diabetes patients after trials showed it reduces the risk of disease progression, Novo Nordisk announced. ...SMALL CRAFT ADVISORY REMAINS ...

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of ...

DR. COHEN SAYS THAT DOESN'T MEAN GREATER ACCESS TO THEM.. AS DEMAND GOES UP.. BUT HE SA Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been ...